For patients who obtain their medication through Biologics by McKesson:
Clinical educators‡ are available to provide:
*This offer is not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, Veterans Affairs, Departments of Defense, TRICARE, or similar federal or state programs.
†Approval is not guaranteed. Sanofi Genzyme reserves the right to modify or discontinue the programs at any time.
‡CABLIVI clinical educators are paid to provide educational services. They don’t provide medical advice. Patients should always consult their physicians with any health care needs.
CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.
The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).
Concomitant use of CABLIVI with any anticoagulant may increase the risk of bleeding. Assess and monitor closely for bleeding with concomitant use.
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.
CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.